Ovid Therapeutics (OVID)
(Delayed Data from NSDQ)
$3.05 USD
0.00 (0.00%)
Updated Mar 28, 2024 03:59 PM ET
After-Market: $3.06 +0.01 (0.33%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for Ovid Therapeutics falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -52.34 | -54.17 | 122.83 | -81.04 | -60.46 |
Depreciation/Amortization & Depletion | 1.60 | 1.38 | 0.24 | 0.31 | 0.26 |
Net Change from Assets/Liabilities | 2.39 | -8.23 | -16.81 | 21.82 | 3.94 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 2.58 | 5.79 | 12.35 | 7.33 | 5.18 |
Net Cash From Operating Activities | -45.78 | -55.23 | 118.61 | -51.58 | -51.09 |
Property & Equipment | -0.04 | -1.22 | -0.18 | -0.13 | -0.06 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -2.44 | -86.46 | -1.63 | 35.04 | -29.80 |
Other Investing Activities | -0.10 | -0.19 | -0.01 | -0.26 | -0.19 |
Net Cash from Investing Activities | -2.58 | -87.88 | -1.82 | 34.65 | -30.04 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.54 | 0.18 | 0.93 | 47.24 | 64.25 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 30.00 | 0.00 | -0.02 | -0.16 | 22.29 |
Net Cash from Financing Activities | 30.54 | 0.18 | 0.90 | 47.07 | 86.54 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -17.83 | -142.93 | 117.69 | 30.14 | 5.41 |
Cash at Beginning of Period | 46.80 | 189.73 | 72.03 | 41.90 | 36.49 |
Cash at End of Period | 28.97 | 46.80 | 189.73 | 72.03 | 41.90 |
Diluted Net EPS | -0.74 | -0.77 | 1.76 | -1.39 | -1.54 |
Fiscal Year End for Ovid Therapeutics falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -52.34 | -37.02 | -25.76 | -13.36 | -54.17 |
Depreciation/Amortization & Depletion | 1.60 | 1.20 | 0.79 | 0.40 | 1.38 |
Net Change from Assets/Liabilities | 2.39 | -1.27 | -1.30 | -0.27 | -8.23 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 2.58 | 3.22 | 2.45 | 1.12 | 5.79 |
Net Cash From Operating Activities | -45.78 | -33.87 | -23.82 | -12.11 | -55.23 |
Property & Equipment | -0.04 | -0.03 | -0.02 | -0.01 | -1.22 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -2.44 | 46.07 | 50.43 | 30.24 | -86.46 |
Other Investing Activities | -0.10 | -0.11 | -0.11 | 0.00 | -0.19 |
Net Cash from Investing Activities | -2.58 | 45.94 | 50.29 | 30.23 | -87.88 |
Uses of Funds
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.54 | 0.50 | 0.28 | 0.07 | 0.18 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 30.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 30.54 | 0.50 | 0.28 | 0.07 | 0.18 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -17.83 | 12.57 | 26.76 | 18.18 | -142.93 |
Cash at Beginning of Period | 46.80 | 46.80 | 46.80 | 46.80 | 189.73 |
Cash at End of Period | 28.97 | 59.37 | 73.55 | 64.98 | 46.80 |
Diluted Net EPS | -0.21 | -0.16 | -0.18 | -0.19 | -0.16 |